MedImmune seeks approval for new drug Respivir would fight respiratory disease

January 05, 1993|By Liz Bowie | Liz Bowie,Staff Writer

MedImmune Inc. said yesterday that it has asked the Food and Drug Administration for approval to market a new drug to prevent a respiratory disease in children.

The Gaithersburg biotechnology company said that Respivir would be used to prevent respiratory syncytial virus (RSV), which is the leading cause of pneumonia in children.

As part of an agreement with physicians who tested the product in five centers nationwide, the company said it could not release data on the results until the work was presented at a scientific conference in May.

The company, which announced the application after the market closed, said it expects substantial profits from the sale of the product, assuming approval from the FDA, a process which could take several years.

The company closed yesterday at $23.25 a share in over-the-counter trading, up 25 cents.

Small children with lung diseases and premature infants are most susceptible to serious cases of RSV, which kills 4,500 people a year in the United States. There is no other product on the market to prevent RSV infection, according to the company.

Baltimore Sun Articles
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.